CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
55.12
-1.49 (-2.63%)
At close: Nov 7, 2025, 4:00 PM EST
55.56
+0.44 (0.79%)
After-hours: Nov 7, 2025, 7:59 PM EST
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $892.00K in the quarter ending June 30, 2025, with 72.53% growth. This brings the company's revenue in the last twelve months to $38.05M, down -81.18% year-over-year. In the year 2024, CRISPR Therapeutics AG had annual revenue of $37.31M, down -89.95%.
Revenue (ttm)
$38.05M
Revenue Growth
-81.18%
P/S Ratio
124.49
Revenue / Employee
$96,819
Employees
393
Market Cap
5.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.31M | -333.89M | -89.95% |
| Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
| Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
| Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
| Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRSP News
- 1 day ago - CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study - Reuters
- 1 day ago - CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering - GlobeNewsWire
- 4 weeks ago - CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform - GlobeNewsWire
- 5 weeks ago - CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress - GlobeNewsWire
- 7 weeks ago - Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track - Seeking Alpha
- 2 months ago - CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 2 months ago - Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade. - Barrons
- 2 months ago - CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha